Drug application
CEPTAZ (CEFTAZIDIME)
Drugs@FDA NDA 050646 · GLAXOSMITHKLINE
Key facts
| Drug name | CEPTAZ |
|---|---|
| Active ingredients | CEFTAZIDIME |
| Application type | NDA |
| Application number | 050646 |
| Company | GLAXOSMITHKLINE |
| Dosage forms | INJECTABLE, INJECTION |
| Strength | 500MG/VIAL |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 2 - New Active Ingredient |
| Latest submission status date | Sep 27, 1990 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: